Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Luxury Meets Cannabis Conference (LMCC) Spring 2023 Edition Returns To Hudson Yards, NYC: May 18 & 19

LMCC Ventures LLC

The Luxury Meets Cannabis Conference (LMCC) today announced its first wave of speakers, retail attendees, and showcasing brands for its Spring 2023 Edition, which returns to Hudson Yards in New York City on May 18 & 19, 2023. Launched in 2018 as a first-of-its-kind B2B event, LMCC has grown into the go-to biannual venue for product discovery and extensive education, connecting visionary CBD and Cannabis wellness, beauty, food/beverage, and lifestyle accessories brands – and their founders – to a powerful combination of hundreds of traditional retail buyers, luxe dispensaries, editorial press, and investors from around the world. 2023: The Year of the Brand “We’ve reimagined the boutique trade show experience by providing an immersive luxury retail environment for our business attendees to discover the finest wellness, beauty, and food & beverage brands in the space,” said LMCC’s Co-Founder & Executive Director Jed Wexler. “And as Cannabis retail comes alive in New York, 2023 truly is ‘The Year of the Brand’ with LMCC being the bridge to a massive new, elevated mainstream CPG wellness category.” In a testament to the mainstreaming of the category, LMCC will welcome a robust roster of industry leaders for two full days of panel discussions – each moderated by a veritable who’s who in media. Speakers: Jacques Tortoroli, CEO, Charlotte’s Web (“The Official CBD of Major League Baseball”) Jake Bullock, Co-Founder & CEO, Cann Tremaine Wright, Cannabis Control Board Chair, New York Office of Cannabis Management Arana Hankin-Biggers, President, Union Square Travel Agency Emily Schildt, Founder & CEO, Pop Up Grocer Amir Zwickel, Founder, SHOWFIELDS Melany Dobson, CEO, Hudson Cannabis & Ben Dobson, President, Hudson Cannabis Media: Tiffany Kary, Bloomberg News Chala June, Contributor, Bon Appétit Brian Underwood, Women’s Health Michael Kusek & Brit Smith, Different Leaf Kelly Kovack, Founder & CEO, BeautyMatter Oset Babür-Winter, Food & Wine Claire McCormack, Beauty Independent Erica La Sala, Beauty Independent Jeremy Berke (‘Cannabis Business Reporter of the Year”) Recently named one of BeautyMatter’s “Top Global Wellness & Beauty Trade Events” and Trade Show Executive Magazine’s “Leading Upcoming Trade Events in North America,” LMCC will present its signature Brand Showcase Studio — a pre-vetted, store-ready exhibition throughout the two-day program featuring keynotes and conversations with speakers, founders, and journalists. The LMCC 2023 Spring Edition will welcome hundreds of buyers from A-tier retail outlets, 50 accepted showcasing brands, 50 industry-leading speakers, and close to 900 global business attendees. Indicating the excitement and opportunity surrounding New York’s just-opened legal Cannabis market, LMCC is slated to host its largest and most impactful event to date. Exclusive New York and National Brand Launches at LMCC Spring 2023 From Charlotte’s Web and the re-rise of CBD wellness to Hudson Cannabis, 1906, Rose Los Angeles, Drew Martin, Dad Grass, PAMOS, and a slew of pioneering New York Cannabis brand launches exclusively during the show, LMCC presents the world’s finest store-ready product portfolios in and outside of the space. View the LMCC Spring 2023 peaker schedule and Brand Showcase Studio line-up at lmccshow.com. Follow LMCC Instagram or LinkedIn. LMCC SPRING 2023 BRAND SHOWCASE STUDIO DIRECTORY Brands can still apply to activate their brands at LMCC Spring 2023 HERE. View the latest Brand Showcase Studio directory HERE. LMCC SPRING 2023 RETAIL BUYER PREVIEW Admission is complimentary only for qualified retail buyers and their teams. Register representatives from traditional/online retailers, hotels/spas, independent wellness boutiques, luxe dispensaries, natural markets, and more HERE. ### Attendee Tickets: Two-day, all-access passes to LMCC Spring 2023 are $695. Purchase passes HERE. About LMCC: Founded in 2018, LMCC Ventures LLC is the parent company of the annual Luxury Meets Cannabis Conference (LMCC) in New York City. LMCC is the premier B2B event connecting A-tier retailers, media, investors, leading dispensaries, and CPG executives to premium CBD, hemp and Cannabis brands — with a keen focus on beauty, wellness, food & beverage. Past participants include retailers like Sephora, Nordstrom, Credo Beauty, and Bloomingdale’s; media including The New York Times, Glossy, Travel & Leisure, O, The Oprah Magazine, and Robb Report; and speakers from Mitch Baruchowitz (Merida Capital Holdings) and Cindy Capobianco (Lord Jones) to Bobbi Brown and Frederic Fekkai. Guidelines & Legal: Cannabis in name only; No smoking or vaping on any kind permitted inside the venue; Illegal products will NOT be allowed on-site Local laws strictly apply. Badge or Pass Required: LMCC is an invite-only B2B trade event not open to the public. A badge or pass is required. Contact Details LMCC Press Katie Shapiro +1 303-882-5596 katie@katieshapiromedia.com Company Website https://www.lmccshow.com/

April 20, 2023 06:30 AM Eastern Daylight Time

ANGLE PLC has opened up "a major market opportunity" with breast cancer partnership

ANGLE PLC

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland joins Thomas Warner from Proactive after announcing a development partnership with BioView. The partnership will see the two firms develop to create a circulating tumour cell (CTC) HER2 assay for breast cancer that could ultimately enable hospitals worldwide to access technology that measures HER2 status in breast cancer patients. Newlands says it has opened up "a major market opportunity" with the partnership. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 20, 2023 04:20 AM Eastern Daylight Time

Video

AVRA Medical Robotics Announces Closing of Merger with CardioVentures

SS Innovations International Inc

McapMediaWire -- AVRA Medical Robotics, Inc. (“the Company”) (OTC: AVMRD ), a medical robotics software and artificial intelligence company, announced that it has closed on its previously announced acquisition by merger of CardioVentures, Inc. The Company also announced that in connection with the closing of the merger, the Company changed its corporate name to SS Innovations International, Inc. (“SSII”), implemented a one-for-ten reverse stock split (the “Reverse Split”), effective April 17, 2023, and underwent certain management changes. CardioVentures, through a subsidiary, owns a controlling interest in Sudhir Srivastava Innovations Pvt. Ltd., an Indian private limited company (“ SSI - India ”). Based in Haryana, India, SSI-India is engaged in the business of developing innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSI Mantra” surgical robotic system and a wide range of surgical instruments capable of supporting a variety of cardiac and other surgical procedures. The Company now intends to focus on the business of SSI-India and has plans to globally expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. https://ssinnovations.com In the merger, holders of the outstanding shares of common stock of CardioVentures (including certain parties who provided interim convertible financing during the pendency of the merger, were issued shares of SSII common stock representing approximately 95% of issued and outstanding shares of SSII post-merger common stock, with the existing shareholders of SSII holding 5% of issued and outstanding shares of SSII common stock post-merger. At closing of the merger, the holders of CardioVentures common stock also received shares of newly designated Series A Non-Convertible Preferred Stock, which entitles them to voting control of the Company. The Company’s common stock began trading on a post-Reverse Split basis at the opening of trading on Monday April 17, 2023. In connection therewith, the Company's ticker symbol will be AMVRD for twenty (20) trading days commencing April 17, 2023, to designate that it is trading on a post-Reverse Split basis. In addition, our post-Reverse Split common stock will trade under the new CUSIP Number 05453U203. As a result of the Reverse Split, every ten pre-Reverse Split shares of common stock outstanding automatically combined into one new share of post-Reverse Split common stock without any action on the part of the holders. The Reverse Split also applies to shares of common stock issuable upon the conversion of outstanding warrants and stock options. No fractional shares will be issued as a result of the Reverse Split. Any fractional shares resulting from the Reverse Split will be rounded up to the nearest whole share on a per shareholder basis. The Company expects that shareholders holding our shares at registered brokerage firms or at the transfer agent will have the Reverse Split transaction processed automatically in their accounts over the next few days. Shareholders holding physical stock certificates may request new certificates evidencing their post-Reverse Split shares by contacting the Company’s transfer agent, VStock Transfer LLC, at info@vstocktransfer.com or (212) 828-8436. The Company announced changes to its management team. At closing of merger, Alen Sands York and Ettore Tomasetti resigned as directors of the Company and Barry F. Cohen, Dr. Ray Powers and Dr. Farhan Taghizadeh resigned as Chief Executive Officer and Acting Chief Financial Officer, Chief Operating Officer, and Chief Medical Officer of the Company, respectively. Mr. Cohen continues as a director of the Company and assumed the office of Chief Operating Officer – Americas. In addition, Dr. Sudhir Srivastava became a director, Chairman and Chief Executive Officer of SSII, Dr. Vishwajyoti P. Srivastava, the son of Dr. Sudhir Srivastava became a director and President and Chief Operating Officer – South Asia and Anup Sethi became Chief Financial Officer of the Company. For further information and details regarding all of the above matters, please see the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission contemporaneously with the issuance of this release. The Report may be viewed at the SEC’s website, www.sec.gov. About SS Innovations International, Inc. SS Innovations International, Inc. (OTC: AVMRD ) is engaged in the business of developing innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSI Mantra” surgical robotic system and a wide range of surgical instruments capable of supporting a variety of surgical procedures including cardiac. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at www.ssinnovations.com Forward-Looking Statements This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or AVRA’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. For Further Information Contact: Barry F. Cohen bcohen@avramedical.com Contact Details Barry F. Cohen bcohen@avramedical.com

April 19, 2023 04:58 PM Eastern Daylight Time

Dear America, Mission Possible: Prevention and Cures Starts Now

The American Center for Cures

I hope this letter finds you and your family in good health. The exceptional leadership and resilience of this nation has been an inspiration to Dr. Rick Boxer and me, prompting us to embark on a vital mission that resonates with every American, regardless of wealth, race, or political affiliation: combating disease. Despite our nation's efforts, we have not achieved the level of prevention and cures necessary to alleviate the suffering and burden of diseases that affect us all. It is time for a paradigm shift, and we believe that every American is in a unique position to help drive this transformation. The American Center for Cures, which we co-founded, aims to establish a fully funded private-sector mission dedicated to preventing and curing the most devastating diseases, such as Alzheimer's, Parkinson's, various forms of cancer, heart disease, diabetes, and all other diseases including orphan diseases. Our vision is to assemble the most successful CEOs in America to lead individual centers focused on these diseases, with each center receiving $36 billion in funding. By combining resources, leadership, focus, and a sense of urgency, we believe we can create a new era in disease prevention and cures. This effort has the potential to be the most significant legacy issue of our lifetimes, impacting not only American families but also the global community. We humbly request Corporate America’s public endorsement and the social support of the American People to provide hope to millions and promote a business-like model of accountability that is currently lacking. Furthermore, we encourage you to urge every member of Congress and the White House to expedite their support for this initiative. We are not merely asking for their backing; we are insisting on it. This mission is for you, your children, and future generations. It is likely that you and your loved ones have been personally affected by a disease that should no longer exist. By embracing this mantle of leadership today, we can make a lasting impact on the lives of countless individuals. Former Secretary of Health Tom Price has stated that the American Center for Cures could rival the greatest achievements in American history. My partner, Dr. Rick Boxer, was recently appointed to the National Cancer Advisory Board by President Biden. We need your voice and skills now more than ever. We commend the extraordinary work of researchers around the world and their commitment to delivering cures. However, a systemic issue exists within the medical use authorization and approval process, and it delays getting cures into the hands of the people who need them now. We’re on the cusp of curing pancreatic, breast, and brain cancer, as well as preventing heart attacks but the current model, because of economic- and process -related obstacles, does not accommodate success. The American Center for Cures is offering a solution to this problem by providing a mission, funding, responsibility, accountability, and leadership, will fundamentally restructure and speed the process of working with the FDA and all relevant parties for authorized cures. Just like the speed of getting the COVID vaccine approved and authorized for use, American Center for Cures is committed to bringing new cures and treatments to patients as quickly and efficiently as possible. We believe that now is the time to harness our global technological advances to establish a process and urgency that will bring these pieces together for the betterment of humanity. By acting today, we can create a lasting legacy in the fight against disease. We are Unity Strong! Best regards, Lou Weisbach Co-founder, The American Center for Cures About American Center for Cures The American Center for Cures (ACC) initiative is a fully funded mission to prevent, treat or cure diseases that plague every American family. The initiative will be funded by the sale of $750B bonds by the Federal Reserve, providing the capital needed to accelerate the current trajectory of medicine. Annual interest will be paid through the licensing of new compounds and drugs to pharmaceutical companies. The principal will be repaid by savings provided to the United States Government through successes in the areas of prevention and cures. The ACC business model will cost the government and taxpayers nothing, making this the single most impactful investment on behalf of the American people in the nation’s history. For more information, please visit https://theamericancenterforcures.org. Contact Details Rainier Communications Jenna Beaucage +1 508-340-6851 jbeaucage@rainierco.com Company Website https://theamericancenterforcures.org

April 19, 2023 01:33 PM Eastern Daylight Time

News Release

NuggMD to Launch the Too-High Hotline on 4/20, Providing Much-Needed Peer Counseling to Those Who Overindulge

NuggMD

With the launch of its Too-High Hotline, NuggMD, the nation's leading medical marijuana telemedicine platform, is helping accidental cannabis overindulgers to find support this 4/20. It's that time of year again. And while 4/20 is arguably a dedicated cannabis users' favorite holiday, it's time to remind our fellow interdimensional explorers to indulge responsibly. States have seen an explosion in much-needed harm reduction measures, thanks to the reduced stigma around cannabis use. Still, many Americans resist seeking help for highly emotional psychedelic experiences because cannabis is still illegal at the federal level. This results in unguided use by novices unprepared to deal with the powerful mental effects, and every year, emergency visits for excess cannabis consumption spike on 4/20. NuggMD is committed to providing educational material to patients explaining the differing intensity and duration between consumption methods, how other cannabis users approach dosing, and how tolerances vary significantly between users. And this 4/20, in the interest of harm reduction, NuggMD is establishing a “Too High Hotline” to provide free, confidential peer support to those who indulge a little too much, despite ample precautions. "It's easy to accidentally overdo it with cannabis," says Kam Babazade, NuggMD co-founder and COO. "Tolerances are so widely varied. Some patients can take a 50mg edible and not feel a thing, while others are overwhelmed by microdoses of 2.5mg. There's no need to feel ashamed! It has happened to most cannabis users at one time or another. The psychological experience can be very intense, and no one should be forced to go it alone because of stigma." Of course, it's appropriate to seek medical attention if a cannabis user has a medical emergency while under the influence. But more often, the problem is a lack of emotional support, which a patient is unlikely to find in an emergency room. That's where the Too High Hotline comes in. NuggMD’s “Too High Hotline” is available to everyone in the United States this 4/20 to offer support during or after their cannabis experience. NuggMD is also educating patients about harm reduction and support options through a dedicated landing page, nationwide email notifications to their network of over a million patients, and additional ongoing campaigns focused on harm reduction and safe consumption. To learn more about NuggMD’s Too High Hotline, please visit https://www.nuggmd.com/support. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in 22 states and growing. They have connected over 1 million patients with their new medical marijuana doctors face-to-face via their state-of-the-art telemedicine platform. NuggMD believes that every person should have the right to access medical cannabis for their qualifying conditions and is fully committed to helping each patient explore all treatment options for their health and well-being. For further information, visit NuggMD.com. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

April 19, 2023 01:21 PM Eastern Daylight Time

News Release

iDenta discusses company's efforts to combat the opioid epidemic with product line of testing

IDenta Corp.

iDenta CEO Amichai Glattstein joins Proactive's Natalie Stoberman to share how the company is tackling the opioid epidemic with its forensic science based products. iDenta is a leading detection and forensic science company that uses the latest in science and technology to provide solutions to law enforcement, military, government agencies and other organizations dealing with the demanding and constantly changing challenges of fighting illicit drugs and terrorist threats globally. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

April 19, 2023 01:13 PM Eastern Daylight Time

Video

News Release

BioVaxys details shareholder value with retention of Maxim to achieve US stock exchange listing

BioVaxys Technology Corp

BioVaxys CEO James Passin joins Natalie Stoberman from the 35th International Papillomavirus Conference in Washington, D.C. to discuss its latest news of retaining New York City-based Maxim Group as its financial advisor and investment banker. Passin says Maxim will handle strategic planning, assessment of potential strategic alliances and capital requirements, and advising the company with respect to the process of obtaining a listing on a US national stock exchange. BioVaxys is a clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

April 19, 2023 01:00 PM Eastern Daylight Time

Video

News Release

1606 Corp. shares revenue growth and distribution strategy for Brio Nutrition, Truz Singles brands

1606 Corp.

1606 Corp. CEO Greg Lambrecht joins Proactive's Natalie Stoberman to discuss how the company plans to build its product placement and distribution network for its Truz Singles and Brio Nutrition revenue generating brands. 1606 Corp. is an acquisition-based CBD distribution company with over 45 individual retail products. 1606 Corp is aggressively acquiring established CBD companies to capture sufficient revenue to list on the NASDAQ stock exchange. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

April 19, 2023 12:58 PM Eastern Daylight Time

Video

News Release

Headline

BioVaxys Technology Corp

April 19, 2023 12:51 PM Eastern Daylight Time

Video

1 ... 137 138 139 140 141 ... 310